Journal of Substance Abuse Treatment

Papers
(The TQCC of Journal of Substance Abuse Treatment is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Hepatitis C treatment outcomes among patients treated in co-located primary care and addiction treatment settings108
Substance use disorders among older populations: What role do race and ethnicity play in treatment and completion?96
C2: editorial board93
JSAT call for papers for special issue: Stimulant use disorder83
Mechanisms of change in an adapted marijuana e-CHECKUP TO GO intervention on decreased college student cannabis use77
COVID-19 and treating incarcerated populations for opioid use disorder67
A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail66
Barriers to accessing treatment for substance use after inpatient managed withdrawal (Detox): A qualitative study56
Community perspectives on supervised consumption sites: Insights from four U.S. counties deeply affected by opioids53
Augmenting substance use treatment in the drug court: A pilot randomized trial of peer recovery support51
The impact of military sexual trauma and gender on receipt of evidence-based medication treatment among veterans with opioid use disorder51
Life satisfaction among individuals with opioid use disorder receiving extended-release naltrexone: A 12-week randomized controlled trial and a 36-week follow-up49
A qualitative study of service engagement and unmet needs among unstably housed people who inject drugs in Massachusetts47
Integrating substance use care into primary care for adolescents and young adults: Lessons learned46
Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data42
Perspectives on electronic portal use among patients treated with medications for opioid use disorder in primary care42
Clinical symptoms and personality traits predict subpopulations of treatment-seeking substance users41
Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail41
Views of barriers and facilitators to continuing methadone treatment upon release from jail among people receiving patient navigation services39
The new services that opioid treatment programs have adopted in response to COVID-1939
C2: editorial board39
Sex-based differences in psychiatric symptoms and opioid abstinence during buprenorphine/naloxone treatment in adolescents with opioid use disorders38
What is success in treatment for opioid use disorder? Perspectives of physicians and patients in primary care settings38
Experiences of stigma among individuals in recovery from opioid use disorder in a rural setting: A qualitative analysis38
Use of non–prescribed buprenorphine in the criminal justice system: Perspectives of individuals recently released from incarceration36
A randomized comparison of 4 vs. 16 weeks of psychosocial treatment for stimulant users36
Massachusetts Justice Community Opioid Innovation Network (MassJCOIN)35
Emergency department interventions for opioid use disorder: A synthesis of emerging models34
What is the relapse risk during treatment? Survivor analysis of single and multiple relapse events in inpatients with alcohol use disorder as part of an observational study32
C2: editorial board31
Serial mediation analysis of treatment-specific processes in two contrasting alcohol treatments30
Suicide safer care in behavioral health settings: A comparative analysis of perceptions, training completion, and practice between mental health and substance use disorder treatment providers30
Al-Anon Intensive Referral (AIR): A qualitative formative evaluation for implementation29
Association between industry sponsorship and author conflicts of interest with outcomes of systematic reviews and meta-analyses of interventions for opioid use disorder29
Facing the future of substance use disorders treatment in Vietnam – A case study for international development and cooperation29
Education and careers were our way out29
Can nicotine replacement therapy be personalized? A statistical learning analysis28
Facilitating engagement of persons with opioid use disorder in treatment for hepatitis C virus infection via telemedicine: Stories of onsite case managers28
Incarceration and compulsory rehabilitation impede use of medication for opioid use disorder and HIV care engagement in Vietnam27
Suboptimal nonmedical qualities of primary care linked with care avoidance among people who use drugs in a Canadian setting amid an integrated health care reform27
A randomized clinical trial evaluating the impact of counselor training and patient feedback on substance use disorder patients' sexual risk behavior27
Associations of retention on buprenorphine for opioid use disorder with patient characteristics and models of care in the primary care setting26
Using machine learning to identify predictors of imminent drinking and create tailored messages for at-risk drinkers experiencing homelessness26
Competing risks of women and men who use fentanyl: “The number one thing I worry about would be my safety and number two would be overdose”26
Stepped-wedge randomized controlled trial of a novel opioid court to improve identification of need and linkage to medications for opioid use disorder treatment for court-involved adults24
A systematic review of integrative medicine for opioid withdrawal24
Targeting women veteran's stress-induced drinking with cognitive reappraisal: Mechanisms and moderators of change24
Adapting methadone inductions to the fentanyl era24
Tobacco smoking and nicotine dependence among patients with respiratory diseases in Vietnam: Status and correlated factors24
Improving geographic access to methadone clinics24
Connecting and disconnecting: Experiences of people with opioid use disorder in intensive outpatient treatment23
Addressing adolescent substance use in an urban pediatric federally qualified health center23
Drug court utilization of medications for opioid use disorder in high opioid mortality communities23
The impact of COVID-19 on substance use disorder treatment in California: Service providers' perspectives23
The impact of social network dynamics on engagement in drug use reduction programs among men and women who use drugs23
Using machine learning to examine predictors of treatment goal change among individuals seeking treatment for alcohol use disorder23
Frequency and recency of non-medical opioid use and death due to overdose or suicide among individuals assessed for risky substance use: A national registry study in Sweden23
Mobile-based brief interventions targeting cannabis-impaired driving among youth: A Delphi study22
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)22
National trends in substance use treatment admissions for opioid use disorder among adults experiencing homelessness22
Redefining recovery: Accounts of treatment experiences of dependent cannabis users in Nigeria22
Latent class analysis of self-reported substance use during incarceration: Gender differences and associations with emotional distress and aggressiveness21
An exploration of thriving over time in recovery21
Adapting and scaling a single site DEA X-waiver training program to a statewide initiative: Implementing GetWaiveredTX21
Development and validation of a claim-based provider-level measurement of use of medications to treat opioid use disorder21
A randomized clinical trial of strengths-based case management to link emergency department patients to opioid use disorder treatment21
Knowledge, attitudes, and behaviors related to the fentanyl-adulterated drug supply among people who use drugs in Oregon20
Implications of posttraumatic growth for the treatment of comorbid substance abuse among survivors of traumatic experiences20
Scoping review of interventions to link individuals to substance use services at discharge from jail20
C2: editorial board20
Recovering from substance use disorders during the early months of the COVID-19 pandemic: A mixed-methods longitudinal study of women in Kansas City20
Engagement patterns with a digital therapeutic for substance use disorders: Correlations with abstinence outcomes19
Patterns of enrollment in a New Orleans women's substance use rehabilitation center19
Beyond harm-producing versus harm-reducing: A qualitative meta-synthesis of people who use drugs' perspectives of and experiences with the extramedical use and diversion of buprenorphine19
Emotion dysregulation and hazardous drinking in relation to suicidal ideation among Spanish-speaking Latinx daily-smokers19
The impact of COVID-19 on health care professionals who are exposed to drug-related deaths while supporting clients experiencing addiction19
Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study19
Recidivism prevention for impaired driving: Longitudinal 5-year outcomes from Quebec's severity-based intervention assignment program19
Where did the specialty behavioral health workforce grow between 2011 and 2019? Evidence from census data19
Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): A national qualitative study19
C2: editorial board19
SMART Recovery International and COVID-19: Expanding the reach of mutual support through online groups19
Increased utilization of buprenorphine and methadone in 2018 compared to 2015 among Seattle-area persons who inject drugs19
Corrigendum to “Feasibility and acceptability of mindful recovery opioid use care continuum (M-ROCC): A concurrent mixed methods study” [Journal of Substance Abuse Treatment 130 (2021) 108415]19
Racial disparities in linkage to care among patients with substance use disorders18
Digital delivery of a contingency management intervention for substance use disorder: A feasibility study with DynamiCare Health18
A pilot randomized clinical trial of mindfulness-oriented recovery enhancement as an adjunct to methadone treatment for people with opioid use disorder and chronic pain: Impact on illicit drug use, he18
Associations between patient experience and clinical outcomes in substance use disorder clinics: Findings from the veterans outcomes assessment survey18
Associations between prescription and illicit stimulant and opioid use in the United States, 2015–202018
Implementation of buprenorphine initiation and warm handoff protocols in emergency departments: A qualitative study of Pennsylvania hospitals18
Contingency management for treatment attendance: A meta-analysis17
C2: editorial board17
Differential impacts of COVID-19 across racial-ethnic identities in persons with opioid use disorder17
C2: editorial board17
Value of family involvement in substance use disorder treatment: Aligning clinical and financing priorities17
TOC (update)17
Comparison of self-reported substance use with biological testing among treatment-seeking patients with opioid use disorder17
Cognitive insight, medication adherence and methamphetamine cessation in people enrolled in a pharmacotherapy trial for methamphetamine use17
Developing a cascade of care for opioid use disorder among individuals in jail16
Associations between relationship quality and treatment-related stress among couples receiving methadone for opioid use disorder16
Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-1916
Mobile low-threshold buprenorphine integrated with infectious disease services16
Follow-up after ED visits for opioid use disorder: Do they reduce future overdoses?16
Alcohol and drug use among bartenders: An at risk population?16
The short-term effectiveness of real-time video counselling on smoking cessation among residents in rural and remote areas: An interim analysis of a randomised trial16
Mobile methadone medication units: A brief history, scoping review and research opportunity16
TOC (update)15
Choice of extended release medication for OUD in young adults (buprenorphine or naltrexone): A pilot enhancement of the Youth Opioid Recovery Support (YORS) intervention15
Impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder15
Parental status and characteristics of women in substance use treatment services: Analysis of electronic patient records15
Substance use treatment in Appalachian Tennessee amid COVID-19: Challenges and preparing for the future15
Predictive validity of the New York State Level of Care for Alcohol and Drug Treatment Referral (LOCADTR) for continuous engagement in treatment among individuals recommended for outpatient care15
Consumer access to buprenorphine and methadone in certified community behavioral health centers: A secret shopper study15
TOC (update)15
How emergency department visits for substance use disorders have evolved during the early COVID-19 pandemic15
Client attitudes toward virtual treatment court15
Prescribing buprenorphine for opioid use disorder in primary care: A survey of French general practitioners in the Sentinelles network15
The effect of nicotine dependence and withdrawal symptoms on use of nicotine replacement therapy: Secondary analysis of a randomized controlled trial in primary care15
Patient-centered primary care and receipt of evidence-based alcohol-related care in the national Veterans Health Administration15
Reducing Opioid Mortality in Illinois (ROMI): A case management/peer recovery coaching critical time intervention clinical trial protocol15
Introduction to a Special Issue: Care and treatment for substance use disorders: Studies from around the world14
Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic14
C2: editorial board14
The role of recovery housing during outpatient substance use treatment14
The effect of cannabis policies on treatment outcomes for cannabis use among U.S. adults14
Impact of a pharmacist-led substance use disorder transitions of care clinic on postdischarge medication treatment retention14
0.3610999584198